Literature DB >> 11021969

Three-dimensional structure of a human pancreatic ribonuclease variant, a step forward in the design of cytotoxic ribonucleases.

J Pous1, A Canals, S S Terzyan, A Guasch, A Benito, M Ribó, M Vilanova, M Coll.   

Abstract

We have determined the crystal structure of a human pancreatic ribonuclease or RNase 1 variant at 1.65 A resolution. Five residues in the N-terminal region were substituted by the corresponding amino acids of the bovine seminal RNase. In addition, a Pro to Ser mutation was present at position 50. The substitution of part of the N terminus has been critical both in improving the expression of this enzyme as a recombinant protein and in achieving its crystallisation. The determination of the crystal structure revealed the characteristic RNase fold including a V-shaped beta-sheet and three alpha-helices. It differs from its bovine RNase orthologue mainly in the loop regions. The active-site cleft shows a similar architecture to that of its bovine counterpart, with the essential residues occupying equivalent positions. In the present structure, however, His119 is displaced as it is in the structure of RNase A at high pH. An interaction model of human ribonuclease with the ribonuclease inhibitor, together with inhibition assays, indicate that, in contrast to RNase A, the modification of the loop beta4beta5 is not enough to avoid inhibition. This study represents the first crystallographic approach to the human enzyme, and should constitute an invaluable tool for the design of ribonuclease variants with acquired cytotoxic properties. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021969     DOI: 10.1006/jmbi.2000.4506

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  6 in total

1.  'Crystal lattice engineering,' an approach to engineer protein crystal contacts by creating intermolecular symmetry: crystallization and structure determination of a mutant human RNase 1 with a hydrophobic interface of leucines.

Authors:  Hidenori Yamada; Taro Tamada; Megumi Kosaka; Kohei Miyata; Shinya Fujiki; Masaru Tano; Masayuki Moriya; Mamoru Yamanishi; Eijiro Honjo; Hiroko Tada; Takeshi Ino; Hiroshi Yamaguchi; Junichiro Futami; Masaharu Seno; Takashi Nomoto; Tomoko Hirata; Motonobu Yoshimura; Ryota Kuroki
Journal:  Protein Sci       Date:  2007-07       Impact factor: 6.725

2.  Interactions crucial for three-dimensional domain swapping in the HP-RNase variant PM8.

Authors:  Pere Tubert; Douglas V Laurents; Marc Ribó; Marta Bruix; Maria Vilanova; Antoni Benito
Journal:  Biophys J       Date:  2011-07-20       Impact factor: 4.033

3.  Role of aspartic acid 121 in human pancreatic ribonuclease catalysis.

Authors:  Deepak Gaur; Janendra K Batra
Journal:  Mol Cell Biochem       Date:  2005-07       Impact factor: 3.396

4.  Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein.

Authors:  R Jeremy Johnson; Jason G McCoy; Craig A Bingman; George N Phillips; Ronald T Raines
Journal:  J Mol Biol       Date:  2007-02-09       Impact factor: 5.469

5.  Structural features for the mechanism of antitumor action of a dimeric human pancreatic ribonuclease variant.

Authors:  Antonello Merlino; Giovanna Avella; Sonia Di Gaetano; Angela Arciello; Renata Piccoli; Lelio Mazzarella; Filomena Sica
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

6.  Functional role of glutamine 28 and arginine 39 in double stranded RNA cleavage by human pancreatic ribonuclease.

Authors:  Md Tabish Rehman; Punyatirtha Dey; Md Imtaiyaz Hassan; Faizan Ahmad; Janendra K Batra
Journal:  PLoS One       Date:  2011-03-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.